Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Glucose-6-phosphate dehydrogenase]

H Fujii1

  • 1Department of Blood Transfusion Medicine, Tokyo Women's Medical College.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A GC box in the bidirectional promoter is essential for expression of the human dihydrofolate reductase and mismatch repair protein 1 genes.

FEBS letters·1992
Same author

[Clinical significance of recombinant human granulocyte colony-stimulating factor (rG-CSF) in the chemotherapy of patients with malignant lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology·1992
Same author

[Superficial and pedunculated signet ring cell carcinoma of the urinary bladder: a case report].

Hinyokika kiyo. Acta urologica Japonica·1992
Same author

Successful pancreatojejunal anastomosis for pancreatoduodenectomy.

Surgery, gynecology & obstetrics·1992
Same author

Polar glycosphingolipids in annelida. A novel series of glycosphingolipids containing choline phosphate from the earthworm, Pheretima hilgendorf.

The Journal of biological chemistry·1992
Same author

[Clinical statistical data of patients with abnormal hemoglobin].

Nihon rinsho. Japanese journal of clinical medicine·1992
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Glucose 6-phosphate dehydrogenase (G6PD) deficiency is a common metabolic disorder affecting 400 million people worldwide. Most variants result from single or double nucleotide substitutions, with Class 1 variants linked to chronic hemolysis near enzyme binding sites.

Area of Science:

  • Biochemistry
  • Genetics
  • Hematology

Context:

  • Glucose 6-phosphate dehydrogenase (G6PD) is crucial for NADPH generation, maintaining reduced glutathione, and synthesizing nucleotides.
  • G6PD deficiency is the most prevalent human metabolic disorder, impacting an estimated 400 million individuals globally.
  • The disorder is characterized by chronic or induced hemolytic anemia, often triggered by drugs or infections.

Purpose:

  • To detail the molecular basis of Glucose 6-phosphate dehydrogenase (G6PD) variants.
  • To analyze the genetic mutations responsible for G6PD deficiency and their clinical manifestations.
  • To investigate the structural implications of mutations on G6PD enzyme function.

Summary:

  • G6PD is an X-linked enzyme essential for red blood cell metabolism, with deficiency leading to hemolytic anemia.

Related Experiment Videos

  • Approximately 73 G6PD variants have been identified, primarily caused by one or two nucleotide substitutions.
  • Class 1 G6PD variants, associated with chronic hemolysis, exhibit mutations near the substrate or NADP binding sites.

    • Impact:

    • Understanding G6PD variants aids in diagnosing and managing hemolytic anemias.
    • Genetic insights into G6PD deficiency can inform population screening and genetic counseling.
    • Molecular characterization of G6PD mutations provides a basis for potential therapeutic strategies.